The GenomeWeb Index, which now has 32 companies, lost 2.6 percent in September while the Dow Jones Industrial Average gained 2 percent over the same period.
Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.
10x CEO and Cofounder Serge Saxonov reflected on how the firm's IPO got so big and how he plans to make the single-cell analysis firm even bigger.
The Pleasanton, California-based single-cell sequencing firm said that net proceeds of the IPO will be approximately $357.5 million.
The single-cell sequencing firm originally said it was looking to raise $100 million in its initial public offering.
Spurred to develop new microfluidic chip technology, 10x told customers not to worry about the transition but told a court there would be "guaranteed hitches."
The single-cell analysis firm plans to use the proceeds to fund general corporate activities and potentially acquire businesses, products, or technologies.
The company markets two tests for skin cancer, including DecisionDx-Melanoma for identifying high-risk Stage I and II cutaneous melanoma patients.
The company markets genetic tests for skin cancer including DecisionDx-Melanoma for identifying high-risk stage I and II cutaneous melanoma patients.
The firm, which markets a clinical immunosequencing assay for leukemia and multiple myeloma, had originally expected to sell its shares at $15 to $17 apiece.
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.